Enliven Therapeutics (ELVN) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 24, 2025, to be held virtually, with all stockholders able to participate, vote, and submit questions online.

• Stockholders will vote on the election of three Class II directors and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal 2025.

• The record date for voting eligibility is April 25, 2025, with 49,066,008 shares outstanding.

• Proxy materials are primarily distributed electronically to reduce environmental impact, with options for mail delivery upon request.

Voting matters and shareholder proposals

• Proposals include electing three Class II directors for terms expiring in 2028 and ratifying Deloitte & Touche LLP as auditor.

• The board recommends voting FOR all director nominees and FOR auditor ratification.

• Shareholders may submit proposals for the 2026 meeting by December 29, 2025, and nominate directors per bylaw procedures.

Board of directors and corporate governance

• The board consists of eight members, six of whom are independent under Nasdaq rules.

• Directors are divided into three classes with staggered three-year terms; Class II nominees are Rahul D. Ballal, Jake Bauer, and Andrew Phillips.

• Board committees include audit, compensation, and nominating/governance, each with independent members and defined charters.

• Board diversity and independence are in compliance with Nasdaq requirements.

• The board separates the roles of Chairman and CEO to reinforce independent oversight.